Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;46(12):3085-3094.
doi: 10.1002/hed.27873. Epub 2024 Jul 23.

Effectiveness and feasibility of selective intra-arterial low dose of cisplatin infusion and concomitant radiotherapy for patients with advanced laryngeal cancer with impaired renal function: A retrospective cohort study

Yuji Imahara  1 , Takeharu Ono  1 , Norimitsu Tanaka  2 , Shun-Ichi Chitose  1 , Fumihiko Sato  1 , Shuichi Tanoue  2 , Takashi Kurita  1 , Yusaku Miyata  2 , Koichiro Muraki  2 , Etsuyo Ogo  2 , Chikayuki Hattori  2 , Toshi Abe  2 , Hirohito Umeno  1
Affiliations

Effectiveness and feasibility of selective intra-arterial low dose of cisplatin infusion and concomitant radiotherapy for patients with advanced laryngeal cancer with impaired renal function: A retrospective cohort study

Yuji Imahara et al. Head Neck. 2024 Dec.

Abstract

Background: Chemoradiation therapy with high-dose cisplatin is the standard regimen against advanced squamous cell carcinoma of the larynx (SCC-L). However, patients with renal dysfunction are ineligible for this regimen. We investigated the effectiveness and feasibility of selective intra-arterial low-dose cisplatin infusion and radiotherapy (modified [m]-RADPLAT) for patients with impaired renal function.

Methods: We retrospectively reviewed the data of 77 patients with SCC-L who received m-RADPLAT.

Results: Fourteen and 63 patients had creatinine clearance (CrCl) values of 30 ≤ CrCl < 60 mL/min and ≥60 mL/min, respectively. The m-RADPLAT regimen led to no significant changes in serum creatinine or CrCl values post-treatment. The 5-year local control, overall survival, and laryngectomy-free survival rates of the CrCl < 60 and ≥60 groups were 90.0% and 90.5%, 100% and 81.8%, and 100% and 79.0%, respectively. Grade 3 or higher toxicity rates were not significantly different between the groups.

Conclusions: The m-RADPLAT regimen yielded favorable survival rates and clinical outcomes in patients with impaired renal function.

Keywords: concurrent intra‐arterial low‐dose cisplatin infusion; laryngeal preservation; radiotherapy; renal dysfunction; squamous cell carcinoma.

PubMed Disclaimer

References

REFERENCES

    1. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349:2091‐2098.
    1. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350:1945‐1952.
    1. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high‐risk squamous‐cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937‐1944.
    1. Szturz P, Wouters K, Kiyota N, et al. Low‐dose vs. high‐dose cisplatin: lessons learned from 59 chemoradiotherapy trials in head and neck cancer. Front Oncol. 2019;9:86.
    1. Jacinto JK, Co J, Mejia MB, Regala EE. The evidence on effectiveness of weekly vs triweekly cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC): a systematic review and meta‐analysis. Br J Radiol. 2017;90:20170442.

MeSH terms

LinkOut - more resources